Metadichol® and Type 2 Diabetes Case Report

P. R. Raghavan

Nanorx Inc.

P.O. Box 131

Chappaqua, NY 10514

USA

email: raghavan@nanorxinc.com

Auhto

rs fin

al dra

ft cop

y

Abstract

Background

Metadichol (1,2) is a Nano emulsion of long-chain alcohols called policosanols which are found in many foods

like rice, wheat, grapes, sugar cane, apple and many others (3). It acts on membrane receptors in cells

throughout the body to stimulate the immune system and inhibit a variety of disease processes, including those

that result in metabolic diseases such as diabetes, obesity and hypertension.

Methods

A 38-year-old male of middle eastern origin was diagnosed as diabetic after complaining of tiredness and bouts

of hunger. He was not on any medication and chose to be treated with Metadichol @ 10 mg per day.

Findings

Metadichol helped to lower his fasting blood sugar level from 300 mg/dl to normal in 6 weeks. His HBA1C was

reduced from 9.8% to 6.2% in 12 weeks. After 32 more months, his diabetic indicators remain normal.

Interpretation

Metadichol is safe and effective in controlling blood sugar and HbA1C levels in humans. Metadichol has been

shown to bind to the vitamin D receptor (2) as an inverse agonist. However, it acts more like a protean agonist

ligand (4) to increase or decrease activity depending on the system. Since Metadichol has no known negative

side effects and consists of natural components of common foods, Metadichol has the potential to serve as a

novel treatment for type 2 diabetes.

Key words: Diabetes. HBA1C, Vitamin D, VDR

Auhto

rs fin

al dra

ft cop

y

Introduction

Globally, it is estimated that 366 million people had diabetes in 2011 (5). The number of people with type 2

diabetes is rapidly increasing in every country and in some low to middle income countries, up to 80% of

people have diabetes. India and China are the most affected countries. Diabetes caused 4.6 million deaths in

2011. By the year 2030, it is estimated that 439 million people will have type 2 diabetes.

Type 2 diabetes is a metabolic disease that can be prevented through lifestyle modification, diet control, and

control of overweight and obesity. Education of the populace is still the key to control this emerging epidemic.

Novel drugs are being developed but despite new insight into the pathophysiology of the disease, no cure is

available in sight. We had previously shown the efficacy of Metadichol in reversing type 1 diabetes (6). The

patient continues to produce insulin 5 years after he stopped using Metadichol. In this case report, we show

Metadichol’s potential use on patients with Type 2 diabetes.

Case Report

A 38 years old man complained of tiredness and bouts of hunger at his annual checkup. A routine blood test

revealed that he had high fasting glucose level of 300 mg/dl. The patient decided against using prescription

drugs and opted to use Metadichol® at 5 mg twice a day. His glucose level was measured and monitored

regularly throughout the first 12 weeks (Figures 1-8).

There was rapid improvement in his condition and by Week 6, his blood glucose levels were under control. By

Week 12, his HbA1C (Figure 7) had dropped from 9.8% to 6.2%. His tiredness was abated within 2 weeks of

starting the regimen. His blood was very thick and dark when he first started using Metadichol but by the end of

Week 6, his blood color was lighter and the blood flow was normal. He continued to use Metadichol at 5 mg per

day and a year later, his glucose and HbA1C remained normal.

Discussion

Metadichol is a Nano emulsion of long-chain lipid alcohols (C-26, C-28 and C-30), which are commonly

known as Policosanols. Metabolism studies in fibroblasts suggest that very long chain fatty alcohols, fatty

aldehydes, and fatty acids are reversibly interconverted in a fatty alcohol cycle (7,8). Since the metabolites of

long chain alcohols are inter converted, a single dosage even at low doses can theoretically have lasting effects.

Metadichol has a particle size of less than 60 nm. We have shown that it binds to the vitamin D receptor (VDR)

as an inverse agonist (2). It is the only known inverse agonist of VDR known in medical literature.

Calcitriol (1,25-Dihydroxy Vitamin D) is the natural ligand for the VDR and acts as an agonist. Protean

agonists act as both positive and negative agonists on the same receptor, depending on the degree of constitutive

activity that is present. If there is no constitutive activity, the agonist would be a positive agonist. When

Auhto

rs fin

al dra

ft cop

y

constitutive activity is present, the Protean agonist would be an inverse agonist (9). Metadichol can also act both

ways, increasing insulin secretion (8) and reducing insulin in hyperinsulinemia (2). Therefore, it behaves more

like a Protean agonist.

Vitamin D is essential to the skeletal system (10) and recent evidence suggests that it also plays a major role in

regulating the immune system, perhaps through the involvement in immune responses to diseases (11). The

mechanism of action of vitamin D in type 2 diabetes is thought to be mediated not only through regulation of

plasma calcium levels, which regulate insulin synthesis and secretion, but also through a direct action on

pancreatic beta-cell function. Therefore, owing to its increasing relevance, this review focuses on the role of

vitamin D in the pathogenesis of type 2 diabetes mellitus (12). Metadichol also shares cross-reactivity with

other nuclear receptors (13). This may explain its activity against a wide range of diseases.

Conclusion

Metadichol is a product made from agricultural waste and is a renewable resource. It has the potential to serve

as an antiviral molecule with a broad spectrum of activity, particularly given that its constituents (long-chain

lipid alcohols) are present in foods commonly consumed on a daily basis and that it has demonstrated no

toxicity at doses of up to 5000 mg/kg (14,15). Metadichol may also serve as a preventive agent for many

tropical diseases given that it strengthens innate immunity through VDR binding. This could represent a first

key step in preventing diseases. Metadichol is ready for large scale testing in countries that are ravaged by

diabetes such as India and China. Once proven on large populations, Metadichol could be used as a preventive

nutritional supplement and a cheaper but more effective substitute for prescription drugs that have been largely

ineffective and have many adverse side effects that add to higher healthcare costs.

Acknowledgements: The author would like to thank Dr. Michel Muller, PhD, General Manager of Micro-

Sphere, Switzerland for sample supply and helpful discussions over the past seven years, and Dr. SC Tang,

PhD, CEO of Generation100 LLC for the collection of data from Metadichol usage on many diseases.

REFERENCES

1. Raghavan PR. 2014. US patent No 8.722.093.

2. Raghavan PR. 2015. US Patent No 9,006,292.

3. Hargrove JL, et.al. Nutritional Significance and Metabolism of Very Long Chain Fatty Alcohols and Acids

from Dietary Waxes; Exp Biol Med (Maywood): 2004 Mar;229(3):215-26.

4.Kenakin T. Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? Mol

Pharmacol: 2007; 72:1393-1402.

5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature:2001

Auhto

rs fin

al dra

ft cop

y

Dec;414(6865):782-787.

6. Raghavan PR. A case report of Type 1 Diabetes. Journal of the Science of Healing Outcomes: 2010; Vol

2(8/9):24.

7. Rizzo WB. Inherited disorders of fatty alcohol metabolism. Mol Genet Metab: 1998; 65:63–73,

8. Rizzo WB, Craft DA, Dammann AL, Phillips MW. Fatty alcohol metabolism in cultured human fibroblasts:

evidence for a fatty alcohol cycle. J Biol Chem: 1987; 262:17412–17419.

9. Neubig RR. Missing Links: Mechanisms of Protean Agonism, Mol Pharmaco: 2007; l71:200–1202.

10. Christakos S, Hewison M, Gardner DG, et al. Vitamin D: Beyond bone. Ann N Y Acad Sci: 2013; 1287:45-

58.

11. Bikle DD. Vitamin D and immune function: Understanding common pathways. Curr Osteoporos Rep: 2009;

7:58-63.

12. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of

type 2 diabetes mellitus. Diabetes Obes Metab: 2008 Mar;10(3):185-97.

13.. Raghavan PR. unpublished work.

14. Alemán CL, Más R, Hernández, et al. A 12-month study of policosanol oral toxicity in Sprague Dawley

rats. Toxicol Lett; 1994; 70:77-87; Alemán, C.L, Más Ferreiro, et al. Carcinogenicity of policosanol in Sprague

Dawley rats: A 24-month study. Teratog Carcinog Mutagen 1994; 14:239-49.

15. Aleman C.L, Puig MN, ElN, E.C., et al., Carcinogenicity of policosanol in mice. An 18-month study. Food

Chem Toxicol: 1995: 33, 573-8.

Figures

Figure 1: Daily Fasting Glucose level before breakfast

Figure 2: Glucose level 1 hour after breakfast

Figure 3: Glucose level before lunch

Figure 4: Glucose level 2 hours after lunch

Figure 5: Glucose level before dinner

Figure 6: Glucose level 2 hours after dinner

Figure 7: HbA1C levels at baseline and at day 84

Figure 8: Glucose level comparison at baseline, average first 41 days and average days 42-84

Note: Glucose units are mg/dl

Auhto

rs fin

al dra

ft cop

y

Figure 2: Glucose level 2 hours after breakfast

Figure 3: Glucose level before lunch

Figure 1: Daily Fasting Glucose level before breakfast

Auhto

rs fin

al dra

ft cop

y

Figure 4: Glucose level 2 hours after lunch

Figure 6: Glucose level 2 hours after dinner

155140

155 159135

104 111 119

179

123 129117

77

176

104 99110

0

55

110

165

220

Bas

elin

e

day

15

day

16

day

17

day

18

day

19

day

20

day

21

day

23

day

24

day

25

day

30

day

31

day

32

day

33

day

34

day

38

Figure 5: Glucose level before dinner

188

127106

126117106110 99 94108

146

91 89 94 85 90 83 93107

7193

11086 76

9375 79 90 87 76

96 85101

0

55

110

165

220

Bas

elin

e

day

6

day

7

day

8

day

9

day

10

day

11

day

12

day

13

day

14

day

15

day

16

day

17

day

18

day

19

day

20

day

21

day

23

day

24

day

25

day

26

day

27

day

30

day

31

day

32

day

34

day

35

day

36

day

37

day

38

day

39

day

40

day

41

Auhto

rs fin

al dra

ft cop

y

Figure 7: HbA1C levels at baseline and at day 84

Figure 8: Glucose level comparison at baseline, average first 41 days and average days 42-84

Auhto

rs fin

al dra

ft cop

y

Board of Editors !

Barry Hoffbrand Former Editor Postgraduate Medical Journal London.,UK.

Iris Bell Professor of Family and Community Medicine (Program in Integrative Medicine) University of Arizona Tucson, Arizona USA

Juliana Brooks Senior Managing Director General Resonance, LLC Havre de Grace, Maryland USA

Effie Chow East West Academy of Healing Arts San Francisco, California USA

Barbara Dossey Director, Holistic Nursing Consultants Co-Director, Nightingale Initiative for Global Health Santa Fe, New Mexico USA

Bart Flick Visiting Professor University of Georgia Athens, Georgia USA

Dr. Krishnaswami C.V Retd. Prof. Clinical Medicine Head. Diabetology Dept, VHS centre Chennai, India.

Viktor Inyushin Doctor of Biology Professor at Al-Farabi Kazakh State University Almaty Kazakhstan

Wayne Jonas President Samueli Institute for Information Biology Alexandria Virginia USA

Brian Josephson Nobel Laureate, Physics Cambridge University, UK

G.B.Jain Formerly, Chief Physician Jassaram Hospital, New Delhi. INDIA.

Mark Mortenson General Resonance, LLC Havre de Grace, Maryland USA

Konstantin Korotkov Professor of Physics St. Petersburg State Technical University St. Petersburg, Russia

Marc Newkirk President, The Lightfield Foundation, Chester, Massachusetts, USA Marilyn Schlitz Director of Research Institute of Noetic Sciences Petaluma, California USA

Richard Smith Former Editor of British Medical Journal Editor, Cases Journal, London. UK

William Tiller Professor Emeritus of Materials Science Stanford University Payson,Arizona,USA

Vladimir Voeikov Professor, Vice-Chairman Faculty of Biology Lomonosov Moscow State University Moscow, Russia

Chris Reynolds Wheatgrass Pty. Ltd. PO Box 3294 Caloundra DC. Qld. 4551 Australia Susan Lark 101, 1st Street, Suite 499 Formerly Adjunct Professor, Stanford University Los Altos, California USA

Andrew Weil Director, Program of Integrative Medicine University of Arizona Tucson, Arizona USA

David Wiebers Emeritus Professor of Neurology Mayo Clinic Rochester, Minnesota, USA

Gopal K Basisht MD Consultant Rheumatologist. 1300 Edgewater Dr. Orlando, Fl. 32804. U.S.A.